0000899243-20-022431.txt : 20200814 0000899243-20-022431.hdr.sgml : 20200814 20200814165338 ACCESSION NUMBER: 0000899243-20-022431 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200812 FILED AS OF DATE: 20200814 DATE AS OF CHANGE: 20200814 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Akinsanya Karen CENTRAL INDEX KEY: 0001797672 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39206 FILM NUMBER: 201106231 MAIL ADDRESS: STREET 1: SCHRODINGER, INC. STREET 2: 120 WEST 45TH STREET, 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Schrodinger, Inc. CENTRAL INDEX KEY: 0001490978 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954284541 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 120 WEST 45TH STREET STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 503-299-1150 MAIL ADDRESS: STREET 1: 120 WEST 45TH STREET STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-12 0 0001490978 Schrodinger, Inc. SDGR 0001797672 Akinsanya Karen C/O SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR NEW YORK NY 10036 0 1 0 0 See Remarks Common Stock 2020-08-12 4 M 0 13377 3.22 A 13377 D Common Stock 2020-08-12 4 M 0 3344 2.92 A 16721 D Common Stock 2020-08-12 4 M 0 3344 2.92 A 20065 D Common Stock 2020-08-12 4 S 0 200 65.085 D 19865 D Common Stock 2020-08-12 4 S 0 2697 66.5257 D 17168 D Common Stock 2020-08-12 4 S 0 7839 67.3469 D 9329 D Common Stock 2020-08-12 4 S 0 2641 68.1807 D 6688 D Common Stock 2020-08-12 4 S 0 100 65.05 D 6588 D Common Stock 2020-08-12 4 S 0 947 66.7291 D 5641 D Common Stock 2020-08-12 4 S 0 1972 67.557 D 3669 D Common Stock 2020-08-12 4 S 0 325 68.4108 D 3344 D Common Stock 2020-08-12 4 S 0 1076 66.6616 D 2268 D Common Stock 2020-08-12 4 S 0 1861 67.5272 D 407 D Common Stock 2020-08-12 4 S 0 407 68.1725 D 0 D Stock Option (right to buy) 3.22 2020-08-12 4 M 0 13377 0.00 D 2028-08-03 Common Stock 13377 40132 D Stock Option (right to buy) 2.92 2020-08-12 4 M 0 3344 0.00 D 2027-10-10 Common Stock 3344 10033 D Stock Option (right to buy) 2.92 2020-08-12 4 M 0 3344 0.00 D 2027-10-10 Common Stock 3344 6689 D These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.77 to $65.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (11) of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.80 to $66.78, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.80 to $67.79, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.80 to $68.76, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.12 to $67.02, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.15 to $68.11, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.31 to $68.58, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.97 to $66.94, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.02 to $67.94, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.03 to $68.31, inclusive. The option was granted on August 3, 2018. The shares underlying the option are scheduled to vest in equal yearly installments from May 14, 2018 through May 14, 2022. The option was granted on October 10, 2017. The shares underlying the option are scheduled to vest in equal yearly installments from August 15, 2017 through August 15, 2021. Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D /s/ Yvonne Tran, as attorney-in-fact for Karen Akinsanya 2020-08-14